HCPLive

Opioid-induced Constipation
The MD Magazine Opioid-induced Constipation condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

New Drug Deemed Effective for Opioid-Induced Constipation
With 259 million painkiller prescriptions written in 2012 alone, according to the Centers for Disease Control and Prevention (CDC), one of the most common side effects experienced by patients being treated for chronic pain is opioid-induced constipation (OIC).
Studies show that nutrient-dense yogurt may benefit individuals with lactose intolerance, constipation and diarrheal diseases, hypertension, cardiovascular diseases, diabetes, and certain types of cancer.
The opioid epidemic began nearly 30 years ago and since that time small steps have been taken to reverse its effects. The question remains whether too much damage has already been done to fix the problems in a timely manner.
For many years the dangers of opioid addiction have been well known. Taking the steps needed to reverse its impact has been slower in taking hold across the country.
Study results show significant regional variations in the types of procedures and tests administered and the number of prescriptions written for patients with irritable bowel syndrome (IBS), as well as in the number of emergency department visits and hospital admissions.
Movantik (naloxegol), an oral peripherally acting mu-opioid receptor antagonist, has been approved by the FDA for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
New guidelines have been issued in relation to the management of irritable bowel syndrome and chronic idiopathic constipation. The updated guidelines were published as a supplement to the August issue of the American Journal of Gastroenterology.

Most Popular

$vacMongoViewPlus$ $vAR$